Cargando…
Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression.
Bone destructive diseases such as periodontitis and rheumatoid arthritis are caused by excessive activation of osteoclasts. Osteoclastogenesis is regulated by Receptor activator of nuclear factor kappa-β ligand (RANKL) produced by osteoclastogenesis supporting cells such as osteoblast and osteocyte....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861591/ https://www.ncbi.nlm.nih.gov/pubmed/31763378 http://dx.doi.org/10.1016/j.bonr.2019.100228 |
_version_ | 1783471393324662784 |
---|---|
author | Narimiya, Tsuyoshi Kanzaki, Hiroyuki Yamaguchi, Yuki Wada, Satoshi Katsumata, Yuta Tanaka, Ken Tomonari, Hiroshi |
author_facet | Narimiya, Tsuyoshi Kanzaki, Hiroyuki Yamaguchi, Yuki Wada, Satoshi Katsumata, Yuta Tanaka, Ken Tomonari, Hiroshi |
author_sort | Narimiya, Tsuyoshi |
collection | PubMed |
description | Bone destructive diseases such as periodontitis and rheumatoid arthritis are caused by excessive activation of osteoclasts. Osteoclastogenesis is regulated by Receptor activator of nuclear factor kappa-β ligand (RANKL) produced by osteoclastogenesis supporting cells such as osteoblast and osteocyte. Previously, we reported that NF-E2-related factor-2 (Nrf2) activation in osteoclast precursors inhibited osteoclastogenesis and bone destruction via induction of anti-oxidation and thereby attenuated intracellular ROS signaling. However, it still remains unknown whether Nrf2 activation in cells other than osteoclasts give any negative influence on supporting property for osteoclastogenesis. Here we discovered that Nrf2 activation in osteoblasts suppresses indirectly osteoclastogenesis via inhibiting the expression of interleukin-6 (IL-6) which promotes osteoclastogenesis. In this study, 5-aminolevulinic acid hydrochloride (ALA) and sodium ferrous citrate (SFC) was used as the Nrf2 activator. in vitro experiments, using osteoblast cell line, MC3T3-E1, revealed that the expression of IL-6 was increased by LPS stimulation, but decreased after ALA/SFC treatment in mRNA and protein levels. Furthermore, RANKL expression was augmented by LPS, which was blocked by ALA/SFC treatment. Neutralizing antibody against IL-6 confirmed that LPS-mediated RANKL augmentation was dependent on IL-6 induction. in vivo experiments with LPS-mediated bone destruction in mice, confirmed that augmented IL-6 expression in osteoblasts by immunochemical analysis. ALA/SFC treatment attenuated LPS-mediated IL-6 upregulation. These results suggest that Nrf2 activation in osteoblasts suppress IL-6 and inflammatory bone destruction. The Nrf2 activator acts not only on osteoclasts but also on osteoblasts, in other word, Nrf2 activation indirectly suppresses osteoclastogenesis. In conclusion, the Nrf2 activator exhibits dual inhibitory effects via direct action on osteoclast and indirect action on osteoclast supporting cells. |
format | Online Article Text |
id | pubmed-6861591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-68615912019-11-22 Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression. Narimiya, Tsuyoshi Kanzaki, Hiroyuki Yamaguchi, Yuki Wada, Satoshi Katsumata, Yuta Tanaka, Ken Tomonari, Hiroshi Bone Rep Article Bone destructive diseases such as periodontitis and rheumatoid arthritis are caused by excessive activation of osteoclasts. Osteoclastogenesis is regulated by Receptor activator of nuclear factor kappa-β ligand (RANKL) produced by osteoclastogenesis supporting cells such as osteoblast and osteocyte. Previously, we reported that NF-E2-related factor-2 (Nrf2) activation in osteoclast precursors inhibited osteoclastogenesis and bone destruction via induction of anti-oxidation and thereby attenuated intracellular ROS signaling. However, it still remains unknown whether Nrf2 activation in cells other than osteoclasts give any negative influence on supporting property for osteoclastogenesis. Here we discovered that Nrf2 activation in osteoblasts suppresses indirectly osteoclastogenesis via inhibiting the expression of interleukin-6 (IL-6) which promotes osteoclastogenesis. In this study, 5-aminolevulinic acid hydrochloride (ALA) and sodium ferrous citrate (SFC) was used as the Nrf2 activator. in vitro experiments, using osteoblast cell line, MC3T3-E1, revealed that the expression of IL-6 was increased by LPS stimulation, but decreased after ALA/SFC treatment in mRNA and protein levels. Furthermore, RANKL expression was augmented by LPS, which was blocked by ALA/SFC treatment. Neutralizing antibody against IL-6 confirmed that LPS-mediated RANKL augmentation was dependent on IL-6 induction. in vivo experiments with LPS-mediated bone destruction in mice, confirmed that augmented IL-6 expression in osteoblasts by immunochemical analysis. ALA/SFC treatment attenuated LPS-mediated IL-6 upregulation. These results suggest that Nrf2 activation in osteoblasts suppress IL-6 and inflammatory bone destruction. The Nrf2 activator acts not only on osteoclasts but also on osteoblasts, in other word, Nrf2 activation indirectly suppresses osteoclastogenesis. In conclusion, the Nrf2 activator exhibits dual inhibitory effects via direct action on osteoclast and indirect action on osteoclast supporting cells. Elsevier 2019-11-01 /pmc/articles/PMC6861591/ /pubmed/31763378 http://dx.doi.org/10.1016/j.bonr.2019.100228 Text en © 2019 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Narimiya, Tsuyoshi Kanzaki, Hiroyuki Yamaguchi, Yuki Wada, Satoshi Katsumata, Yuta Tanaka, Ken Tomonari, Hiroshi Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression. |
title | Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression. |
title_full | Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression. |
title_fullStr | Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression. |
title_full_unstemmed | Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression. |
title_short | Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression. |
title_sort | nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting il-6 expression. |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861591/ https://www.ncbi.nlm.nih.gov/pubmed/31763378 http://dx.doi.org/10.1016/j.bonr.2019.100228 |
work_keys_str_mv | AT narimiyatsuyoshi nrf2activationinosteoblastssuppressesosteoclastogenesisviainhibitingil6expression AT kanzakihiroyuki nrf2activationinosteoblastssuppressesosteoclastogenesisviainhibitingil6expression AT yamaguchiyuki nrf2activationinosteoblastssuppressesosteoclastogenesisviainhibitingil6expression AT wadasatoshi nrf2activationinosteoblastssuppressesosteoclastogenesisviainhibitingil6expression AT katsumatayuta nrf2activationinosteoblastssuppressesosteoclastogenesisviainhibitingil6expression AT tanakaken nrf2activationinosteoblastssuppressesosteoclastogenesisviainhibitingil6expression AT tomonarihiroshi nrf2activationinosteoblastssuppressesosteoclastogenesisviainhibitingil6expression |